Difference between revisions of "Clodronate (Bonefos)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.<ref name="insert">[http://www.bayerresources.com.au/resources/uploads/PI/file9300.pdf Clodronate (Bonefos) package insert]</ref><ref>[[Media:Clodronate.pdf | Clodronate (Bonefos) package insert (locally hosted backup)]]</ref> | Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.<ref name="insert">[http://www.bayerresources.com.au/resources/uploads/PI/file9300.pdf Clodronate (Bonefos) package insert]</ref><ref>[[Media:Clodronate.pdf | Clodronate (Bonefos) package insert (locally hosted backup)]]</ref> | ||
| Line 9: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ===[[Multiple myeloma]]=== | ||
| + | * '''MRC Myeloma IX:''' Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11;376(9757):1989-99. Epub 2010 Dec 3. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62051-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639680/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21131037 PubMed] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/clodronate-patient-drug-information Clodronate (Bonefos) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/clodronate-patient-drug-information Clodronate (Bonefos) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/clodronate-patient-drug-information Clodronate (Bonefos) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/clodronate-patient-drug-information Clodronate (Bonefos) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | '''Not FDA approved; used in several other countries (Canada, Australia, the United Kingdom, Italy, others).''' | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Generic names:''' clodronate disodium, clodronic acid disodium tetrahydrate | ||
| + | *'''Brand names:''' Clasteon, Clastoban, Climaclod, Clodeosten, Clodran, Clodron, Clody, Difosfonal, Disdual, Lodronat, Loron, Lytos, Mebonat, Moticlod, Niklod, Ossiten, Ostac, Osteonorm, Osteostab, Sindronat | ||
==References== | ==References== | ||
| Line 17: | Line 23: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
[[Category:Bisphosphonates]] | [[Category:Bisphosphonates]] | ||
Revision as of 14:50, 14 July 2018
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Multiple myeloma
- MRC Myeloma IX: Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11;376(9757):1989-99. Epub 2010 Dec 3. link to original article link to PMC article PubMed
Patient drug information
History of changes in FDA indication
Not FDA approved; used in several other countries (Canada, Australia, the United Kingdom, Italy, others).
Also known as
- Generic names: clodronate disodium, clodronic acid disodium tetrahydrate
- Brand names: Clasteon, Clastoban, Climaclod, Clodeosten, Clodran, Clodron, Clody, Difosfonal, Disdual, Lodronat, Loron, Lytos, Mebonat, Moticlod, Niklod, Ossiten, Ostac, Osteonorm, Osteostab, Sindronat